#USA #New York #EyePoint Pharmaceuticals #DURAVYU #LUGANO trial

EyePoint Pharmaceuticals Under Investigation Following Major Stock Decline

On August 17, 2026, EyePoint Pharmaceuticals (NASDAQ: EYPT) experienced a staggering decline in its stock value, opening approximately 70% lower. The drastic drop followed the company's announcement that its new treatment, DURAVYU, did not achieve the prespecified primary endpoint in the Phase 3 LUGANO trial related to wet age-related macular degeneration (AMD). This news has raised significant concerns among investors and prompted an investigation by law firm Levi & Korsinsky on behalf of those who suffered financial losses.

The LUGANO Trial and Its Implications

The Phase 3 LUGANO trial was designed to evaluate the efficacy of DURAVYU against the well-established treatment, aflibercept. Specifically, the trial sought to measure changes in best-corrected visual acuity. However, the reported results indicated that DURAVYU failed to meet this critical benchmark. Despite some favorable secondary outcomes, including a reported 42% reduction in treatment burden, the failure of the primary endpoint has overshadowed these findings. This significant oversight has raised questions about the management's transparency regarding trial risks, particularly concerning the symptomatic patients involved in the study.

Impact on Stock and Investor Sentiment

Following the announcement of the trial results, EyePoint’s share price dropped sharply, falling by $10.69 at the opening, equivalent to a decline of 72.47%. By midday, the shares were still trading down over 68%. The fallout from this unexpected turn of events has potentially left many investors at a substantial loss, prompting calls for them to review their eligibility for recovery under the ongoing investigation led by Levi & Korsinsky.

During an investor call, EyePoint's President and CEO, Jay S. Duker, acknowledged that while some of the patients involved in the trial presented challenging anatomy, the results nevertheless failed to meet the expectations set prior to the trial’s commencement. The mention of “asymmetric patients” raised eyebrows since this had not been disclosed as a potential risk to stakeholders prior to the trial outcome.

Investors Encouraged to Act

Investors who suffered losses from their investment in EyePoint are encouraged to take action. Levi & Korsinsky is offering a no-cost evaluation to help assess potential claims for recovery. The firm has a strong track record of representing aggrieved shareholders and could help navigate the securities fraud claims that may arise from this incident.

If you or someone you know invested in EYPT stock, it is crucial to gather brokerage records demonstrating purchase details, including dates and quantities, to outline losses incurred. The firm is committed to providing a comprehensive evaluation of the case to investors considering participation in this investigation.

It's important to note that past performance does not guarantee similar future results; however, numerous successful recoveries have positioned Levi & Korsinsky as a robust player in securities litigation.

Conclusion

As the dust settles from this tumultuous period for EyePoint Pharmaceuticals, investors are left grappling with the implications of the failed trial results and the subsequent plunge in share price. Staying informed and taking appropriate action can be crucial for those seeking to recoup their losses in the aftermath of the LUGANO trial disappointments. Investors interested in evaluating potential claims are encouraged to contact Levi & Korsinsky directly to explore their options in this ongoing investigation.